High-throughput methylation profiling by MCA coupled to CpG island microarray.

An abnormal pattern of DNA methylation occurs at specific genes in almost all neoplasms. The lack of high-throughput methods with high specificity and sensitivity to detect changes in DNA methylation has limited its application for clinical profiling. Here we overcome this limitation and present an improved method to identify methylated genes genome-wide by hybridizing a CpG island microarray with amplicons obtained by the methylated CpG island amplification technique (MCAM). We validated this method in three cancer cell lines and 15 primary colorectal tumors, resulting in the discovery of hundreds of new methylated genes in cancer. The sensitivity and specificity of the method to detect hypermethylated loci were 88% and 96%, respectively, according to validation by bisulfite-PCR. Unsupervised hierarchical clustering segregated the tumors into the expected subgroups based on CpG island methylator phenotype classification. In summary, MCAM is a suitable technique to discover methylated genes and to profile methylation changes in clinical samples in a high-throughput fashion.

[1]  S. Baylin,et al.  Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. , 1999, Cancer research.

[2]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[3]  S. Cross,et al.  Purification of CpG islands using a methylated DNA binding column , 1994, Nature Genetics.

[4]  S. Maheswaran,et al.  Expression of the NF-κB-responsive gene BTG2 is aberrantly regulated in breast cancer , 2004, Oncogene.

[5]  川端 良成.  Defective Apoptotic Signal Transduction Pathway Downstream of Caspase-3 in Human B-Lymphoma Cells : A Novel Mechanism of Nuclear Apoptosis Resistance , 1999 .

[6]  G. Liang,et al.  Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. , 1997, Cancer research.

[7]  E. Tajara,et al.  LHX6 is a sensitive methylation marker in head and neck carcinomas , 2006, Oncogene.

[8]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[9]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[10]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[11]  Michael Black,et al.  Role of transposable elements in heterochromatin and epigenetic control , 2004, Nature.

[12]  Tim Hui-Ming Huang,et al.  Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. , 2002, Genes & development.

[13]  T. Ushijima,et al.  Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. , 2006, Cancer research.

[14]  N. Ahuja,et al.  Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Kaneda,et al.  Identification of silencing of nine genes in human gastric cancers. , 2002, Cancer research.

[16]  司履生.  Cancer epigenetics , 2006 .

[17]  T. Sugimura,et al.  Genetic and epigenetic alterations in carcinogenesis. , 2000, Mutation research.

[18]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[19]  T. Rauch,et al.  MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. , 2006, Cancer research.

[20]  W. Lam,et al.  Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells , 2005, Nature Genetics.

[21]  A. Sakurada,et al.  Genome-wide profiling of promoter methylation in human , 2006, Oncogene.

[22]  M. Toyota,et al.  Epigenetic changes in solid and hematopoietic tumors. , 2005, Seminars in oncology.

[23]  M. de Silva,et al.  Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. , 2005, Cancer genetics and cytogenetics.

[24]  Igor Jurisica,et al.  CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome , 2005, Nucleic acids research.

[25]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Holger Moch,et al.  Impaired Expression of the Cell Cycle Regulator BTG2 Is Common in Clear Cell Renal Cell Carcinoma , 2004, Cancer Research.

[27]  J. Issa,et al.  P14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. , 2003, Gastroenterology.

[28]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[29]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[30]  C Eng,et al.  Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. , 2001, Human molecular genetics.

[31]  F. Ajchenbaum‐Cymbalista,et al.  Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. , 2004, Blood.

[32]  C. M. Chen,et al.  Dissecting complex epigenetic alterations in breast cancer using CpG island microarrays. , 2001, Cancer research.